Serum miRNA Profiling for Early PDAC Diagnosis and Prognosis: A Retrospective Study.
PDAC
expression profiling
miRNAs
survival
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
20 07 2021
20 07 2021
Historique:
received:
26
04
2021
revised:
29
06
2021
accepted:
15
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Tumor stage predicts pancreatic cancer (PDAC) prognosis, but prolonged and short survivals have been described in patients with early-stage tumors. Circulating microRNA (miRNA) are an emerging class of suitable biomarkers for PDAC prognosis. Our aim was to identify whether serum miRNA signatures predict survival of early-stage PDAC. Serum RNA from archival 15 stage I-III PDAC patients and 4 controls was used for miRNAs expression profile (Agilent microarrays). PDAC patients with comparable age, gender, diabetes, jaundice and surgery were classified according to survival: less than 14 months (7/15 pts, group A) and more than 22 months (8/15 pts, group B). Bioinformatic data analysis was performed by two-class Significance Analysis of Microarray (SAM) algorithm. Binary logistic regression analyses considering PDAC diagnosis and outcome as dependent variables, and ROC analyses were also performed. 2549 human miRNAs were screened out. At SAM, 76 differentially expressed miRNAs were found among controls and PDAC (FDR = 0.4%), the large majority (50/76, 66%) of them being downregulated in PDAC with respect to controls. Six miRNAs were independently correlated with early PDAC, and among these, A series of serum miRNAs was identified as potentially useful for the early diagnosis of PDAC, and for establishing a prognosis.
Sections du résumé
BACKGROUND
Tumor stage predicts pancreatic cancer (PDAC) prognosis, but prolonged and short survivals have been described in patients with early-stage tumors. Circulating microRNA (miRNA) are an emerging class of suitable biomarkers for PDAC prognosis. Our aim was to identify whether serum miRNA signatures predict survival of early-stage PDAC.
METHODS
Serum RNA from archival 15 stage I-III PDAC patients and 4 controls was used for miRNAs expression profile (Agilent microarrays). PDAC patients with comparable age, gender, diabetes, jaundice and surgery were classified according to survival: less than 14 months (7/15 pts, group A) and more than 22 months (8/15 pts, group B). Bioinformatic data analysis was performed by two-class Significance Analysis of Microarray (SAM) algorithm. Binary logistic regression analyses considering PDAC diagnosis and outcome as dependent variables, and ROC analyses were also performed.
RESULTS
2549 human miRNAs were screened out. At SAM, 76 differentially expressed miRNAs were found among controls and PDAC (FDR = 0.4%), the large majority (50/76, 66%) of them being downregulated in PDAC with respect to controls. Six miRNAs were independently correlated with early PDAC, and among these,
CONCLUSIONS
A series of serum miRNAs was identified as potentially useful for the early diagnosis of PDAC, and for establishing a prognosis.
Identifiants
pubmed: 34356909
pii: biomedicines9070845
doi: 10.3390/biomedicines9070845
pmc: PMC8301411
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Seventh Framework Programme
ID : 306031
Références
Biomed Pharmacother. 2017 Dec;96:1246-1252
pubmed: 29217161
Front Oncol. 2020 Feb 04;10:44
pubmed: 32117716
Nat Rev Cancer. 2002 Dec;2(12):897-909
pubmed: 12459728
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
pubmed: 24890451
Digestion. 1997;58(6):536-41
pubmed: 9438599
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
pubmed: 12011421
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Theranostics. 2021 Jan 1;11(6):2755-2769
pubmed: 33456571
Oncotarget. 2020 Mar 10;11(10):913-923
pubmed: 32206188
Oncol Lett. 2019 Mar;17(3):3387-3391
pubmed: 30867774
Microrna. 2017;6(1):2-16
pubmed: 27928946
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
J Clin Oncol. 2009 Apr 10;27(11):1806-13
pubmed: 19273710
PLoS One. 2015 Oct 28;10(10):e0141448
pubmed: 26509672
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gastroenterology. 2016 Jan;150(1):48-63
pubmed: 26385075
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Nat Commun. 2015 Apr 09;6:6744
pubmed: 25855536
Diagnostics (Basel). 2020 Oct 24;10(11):
pubmed: 33114412
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
RNA Biol. 2020 Oct;17(10):1416-1426
pubmed: 32456538
Ann Surg Oncol. 2021 Apr;28(4):2235-2245
pubmed: 33393045
Genes Dev. 2006 May 15;20(10):1218-49
pubmed: 16702400
Biomed Pharmacother. 2015 Apr;71:64-9
pubmed: 25960217
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409
pubmed: 32827580
Ann Surg. 2013 Aug;258(2):336-46
pubmed: 23470568
CA Cancer J Clin. 2014 Sep-Oct;64(5):311-36
pubmed: 25104502
Clin Chem Lab Med. 2019 Jun 26;57(7):932-953
pubmed: 30838832
Cancer Lett. 2017 Jan 1;384:94-100
pubmed: 27693459
Pancreatology. 2015 Jan-Feb;15(1):8-18
pubmed: 25547205
Cancers (Basel). 2020 Nov 19;12(11):
pubmed: 33227890
RNA. 2007 Jan;13(1):151-9
pubmed: 17105992
Methods Enzymol. 2006;411:134-93
pubmed: 16939790
Nucleic Acids Res. 2011 Jan;39(Database issue):D163-9
pubmed: 21071411
Future Oncol. 2013 Jul;9(7):917-9
pubmed: 23837751
FEBS Lett. 2011 Jan 3;585(1):207-13
pubmed: 21112326
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188423
pubmed: 32871244
Cancer Biol Ther. 2013 Dec;14(12):1104-12
pubmed: 24025412
JAMA Surg. 2016 Apr;151(4):338-45
pubmed: 26581025
BMC Cancer. 2017 Nov 09;17(1):730
pubmed: 29121858
Mol Biol Rep. 2019 Aug;46(4):4175-4183
pubmed: 31123908
Sci Rep. 2018 Jul 10;8(1):10383
pubmed: 29991730
JAMA. 2014 Jan 22-29;311(4):392-404
pubmed: 24449318
Gastroenterology. 2015 Nov;149(6):1501-10
pubmed: 26253305
Cancer Metastasis Rev. 2021 Mar;40(1):355-371
pubmed: 33398620
Oncol Lett. 2020 Apr;19(4):2727-2732
pubmed: 32218824
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8801-8811
pubmed: 32964968
Bioinformatics. 2009 Oct 15;25(20):2685-91
pubmed: 19628505
Cancer Cell Int. 2020 Sep 10;20:443
pubmed: 32943991
Biochem Pharmacol. 2021 Jul;189:114357
pubmed: 33279497
J Gastrointest Surg. 2020 Oct;24(10):2409-2415
pubmed: 32394126
Eur J Med Res. 2017 Nov 29;22(1):51
pubmed: 29187262
Onco Targets Ther. 2020 Jan 14;13:389-399
pubmed: 32021284
Nucleic Acids Res. 2011 Sep 1;39(16):7223-33
pubmed: 21609964
Curr Opin Cell Biol. 2013 Apr;25(2):233-40
pubmed: 23312066